Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Biotechnology

Healthcare
$149.40 -2.22%

-$6.27 today

Market cap
$20.01B
Beta
0.27
P/E (TTM)
63.6
EPS (TTM)
$4.34
52W Low $273.11High $495.55

Volume 2.52M

Average 1.11M

ALNY Long-term Debt

Borrowings due after more than one year.

Alnylam Pharmaceuticals, Inc.NASDAQ: ALNY

Long-term Debt · Q2 FY2026 · quarter ended Jun 2026

Long-term debt broadly unchanged from a year ago

Long-term debt stood at $1.01B at the end of Q2 FY2026, down 1.5% from a year earlier and up 0.2% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.

Context

  • Long-term debt amounted to 18.2% of total assets at the end of Q2 FY2026, down 4.3 pp from a year earlier.
  • Long-term debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -1.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.01B+0.2% QoQ
Last fiscal yearDec 2025
$1.01B-1.6% YoY
Year agoJun 2025
$1.03B-1.5% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.5%——
1 year-1.6%——
3-year CAGR-0.3%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
1.01B USD
Year-over-year change
-1.6%
4-year CAGR
+10.5%

Long-term Debt vs competitors

How ALNY compares with its peers on the latest reported figures

  • ALNY's Jun 2026 long-term debt of $1.01B is the 2nd highest of the 6 companies compared; the peer median is $61.4M.
  • Its year-over-year change of -1.5% is the lowest of 3, against a peer median of +242.2%.
  • Long-term debt amounts to 18.2% of total assets for ALNY, versus a peer median of 8.1%.
ALNY Competitors Peer median
Long-term Debt for ALNY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IONSIonis Pharmaceuticals, Inc.Sep 2026$1.75B +194.0%+17.1%60.2%
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$1.01B -1.5%-0.3%18.2%
ARWRArrowhead Pharmaceuticals, Inc.Sep 2026$838.88M +290.4%+46.2%48.3%
NTLAIntellia Therapeutics, Inc.Mar 2026$61.4M ——8.1%
SLNSilence Therapeutics plcMar 2026$0 ——0.0%
WVEWave Life Sciences Ltd.Mar 2026$0 ——0.0%
Peer median (excluding ALNY) $61.4M+242.2%+31.7%8.1%

Competitors are the stored peer set for ALNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents819.98M866.39M812.69M966.43M1.66B
Short-term Investments1.62B1.33B1.63B1.73B1.25B
Net Receivables198.57M237.96M327.79M405.31M777.57M
Inventory86.36M128.96M89.15M78.51M82.72M
Other Current Assets0132.92M126.38M116.96M281.89M
Total Current Assets2.81B2.69B2.98B3.3B4.05B
Property, Plant & Equipment (Net)733.63M738.63M725.79M693.93M708.06M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets0010.1M116.86M125.98M
Other Non-current Assets101.1M115.48M111.29M133.9M81.63M
Total Non-current Assets834.73M854.11M847.18M944.7M915.67M
Total Assets3.64B3.55B3.83B4.24B4.97B
Account Payables73.43M98.09M55.52M88.42M115.72M
Short-term Debt00000
Tax Payables00000
Deferred Revenue149.48M42.11M102.75M55.48M4.85M
Other Current Liabilities130.66M170.98M177.16M421.2M477.27M
Total Current Liabilities695.71M767.92M967.79M1.19B1.47B
Long-term Debt675.7M1.02B1.02B1.02B1.01B
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)152.36M193.79M188.18M00
Other Non-current Liabilities1.25B1.46B1.63B1.73B1.48B
Total Non-current Liabilities2.36B2.94B3.08B2.99B2.71B
Total Liabilities3.06B3.7B4.05B4.17B4.18B
Common Stock1.2M1.24M1.26M1.29M1.32M
Retained Earnings(5.44B)(6.57B)(7.01B)(7.29B)(6.7B)
Accumulated OCI(33.26M)(44.65M)(23.38M)(34.52M)(20.1M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity588.2M(158.22M)(220.64M)67.09M789.18M
Total Debt997.59M1.32B1.31B1.3B1.28B
Net Debt177.62M453.85M492.7M329.62M(378.86M)

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Intrinsic Alpha fair value

Locked

Current Price

$149.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.